Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Paul, Paik"'
Autor:
Adam Buckholz, Lindsay Clarke, Paul Paik, Arun Jesudian, Robert Schwartz, Ana Krieger, Russell Rosenblatt, Robert S. Brown, Jr
Publikováno v:
Hepatology Communications, Vol 7, Iss 2, Pp e0002-e0002 (2023)
Background and Aims:. Covert HE (CHE) is a common early stage of HE associated with poor outcomes. Available neuropsychiatric diagnostic testing is underutilized and has significant clinical limitations. Sleep deterioration is consistently associated
Externí odkaz:
https://doaj.org/article/58e0b19e4250444dad3b5c5489b38bc9
Autor:
Omid, Savari, Christopher, Febres-Aldana, Jason C, Chang, Rachel E, Fanaroff, Katia, Ventura, Francis, Bodd, Paul, Paik, Murty, Vundavalli, Anjali, Saqi, Frederic B, Askin, William D, Travis, Natasha, Rekhtman
Publikováno v:
Histopathology. 82:242-253
Thyroid transcription factor 1 (TTF1) and p40 are widely-utilized diagnostic markers of lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC), respectively. Diffuse coexpression of TTF1 and p40 has been described in only rare case reports. In
Autor:
Alexander Drilon, Ahmet Zehir, Paul Paik, Natasha Rekhtman, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Bob T. Li, Ryma Benayed, Ronglai Shen, Deepu Alex, Todd Hembrough, Fabiola Cecchi, Yuan Tian, Kerry Scott, Christina Falcon, Alex Makhnin, Caroline G. McCarthy, Olivia Wilkins, Jeffrey Girshman, Lukas Delasos, Andrew Chow, Jason Chang, A. Rose Brannon, Michael Offin, Robin Guo
Supplementary Figures S1-S6, Table S1-S3, and eMethods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c98a01f999507585f572e63c4b27511
https://doi.org/10.1158/1078-0432.22478177.v1
https://doi.org/10.1158/1078-0432.22478177.v1
Autor:
Alexander Drilon, Ahmet Zehir, Paul Paik, Natasha Rekhtman, Maria E. Arcila, Mark G. Kris, Charles M. Rudin, Bob T. Li, Ryma Benayed, Ronglai Shen, Deepu Alex, Todd Hembrough, Fabiola Cecchi, Yuan Tian, Kerry Scott, Christina Falcon, Alex Makhnin, Caroline G. McCarthy, Olivia Wilkins, Jeffrey Girshman, Lukas Delasos, Andrew Chow, Jason Chang, A. Rose Brannon, Michael Offin, Robin Guo
Purpose:MET tyrosine kinase inhibitors (TKIs) can achieve modest clinical outcomes in MET exon 14–altered lung cancers, likely secondary to primary resistance. Mechanisms of primary resistance remain poorly characterized and comprehensive proteomic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a29c8230760e2c9e1f14ea1b86800ba
https://doi.org/10.1158/1078-0432.c.6529874
https://doi.org/10.1158/1078-0432.c.6529874
Autor:
Hiroki Sato, Daisuke Kubota, Huan Qiao, Achim Jungbluth, Natasha Rekhtman, Adam J. Schoenfeld, Helena A. Yu, Gregory J. Riely, Shinichi Toyooka, Christine M. Lovly, Paul Paik, Marc Ladanyi, Pang-Dian Fan
Publikováno v:
JCO Precision Oncology.
PURPOSE The identification of novel oncogenic driver alterations and novel mechanisms of acquired resistance (AR) is the key for further development of personalized therapy. The current study investigates the potential role of YES1 amplification as a
Autor:
Patrick H. Lizotte, Paul Paik, Liviu Niculescu, Seng-Lai H. Tan, David Bohr, Elham Gharakhani, Ralf Reiners, Rachel Salazar, Avanish Varshney, Shiv Ram Krishn, Pradip Nair, Cloud Paweletz
Publikováno v:
Cancer Research. 83:6677-6677
Background: BCA101 is a bispecific antibody targeting EGFR and TGF-β. TGF-β pathway activation is a hallmark of human immune-excluded tumors, and TGF-β expression is associated with resistance to anti-PD-1 blockade. Neutralization of TGF-β remove
Autor:
Xiuning Le, Lingzhi Hong, Chuck Hensel, Rongrong Chen, Haley Kemp, Niamh Coleman, Christine A. Ciunci, Stephen V. Liu, Marcelo V. Negrao, Jennifer Yen, Xuefeng Xia, Juergen Scheuenpflug, Christopher Stroh, Dilafruz Juraeva, Anne Tsao, David Hong, Victoria Raymond, Paul Paik, Jianjun Zhang, John V. Heymach
Publikováno v:
JCO Precision Oncology
PURPOSE MET exon 14 skipping alterations ( METex14) comprise a diverse set of actionable oncogene drivers in non–small-cell lung cancer (NSCLC). Recent studies have established the efficacy of tyrosine kinase inhibitors for this patient population.
Autor:
Natasha Leighl, Christine Bestvina, Jyoti Patel, Xiuning Le, Remi Veillon, Ian Anderson, Ingel Demedts, Marina Chiara Garassino, Julien Mazières, Masahiro Morise, Egbert Smit, S Peter Eggleton, Aurora O’Brate, Gordon Otto, Rolf Bruns, Karl Maria Schumacher, Paul Paik
Publikováno v:
Neuro-Oncology Advances. 4:i22-i22
BACKGROUND Brain metastases (BMs) occur in 20–40% of patients with METex14 skipping NSCLC. Tepotinib, a highly selective MET inhibitor, demonstrated an objective response rate (ORR) of 49.1% and median duration of response (mDOR) of 13.8 months, in
Autor:
Masahiro Morise, Hiroshi Sakai, Terufumi Kato, Shingo Matsumoto, Toru Kumagai, Tomohiro Sakamoto, Takaaki Tokito, Shinji Atagi, Toshiyuki Kozuki, Hiroaki Takeoka, Kenichi Chikamori, Naofumi Shinagawa, Hiroshi Tanaka, Tomonori Hirashima, S Peter Eggleton, Rolf Bruns, Gordon Otto, Paul Paik
Publikováno v:
Annals of Oncology. 33:S475
Autor:
Wanyuan Cui, Nick Brown, Victoria Brown, Ramesh Bulusu, Arshi Denton, Joanne Evans, Martin Forster, Dionysis Papadatos-Pastos, Loredana Pellegrino, Nessa Walsh, Rolf Bruns, Gordon Otto, Paul Paik
Publikováno v:
Lung Cancer. 165:S38-S39